CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells

Immunity

Volumn 12, Issue 6, 2000, Pages 677-686

  Qin, Zhihai ^a   Blankenstein, Thomas ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL KILLING; CONTROLLED STUDY; EFFECTOR CELL; GENETIC TRANSFECTION; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR REJECTION;

EID: 0033662405     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)80218-6     Document Type: Article

References (44)

1. The IFN gamma receptor: A paradigm for cytokine receptor signaling
2. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes
3. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
4. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer
5. Cellular responses to interferon-gamma
6. Tumor antigens recognized by T lymphocytes
7. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation
8. Tumor cell responses to IFN gamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
9. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors
10. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
11. A macrophage mRNA selectively induced by gamma-interferon encodes a member of the platelet factor 4 family of cytokines
12. The molecular cell biology of interferon-gamma and its receptor
13. Antiangiogenic gene therapy
14. Recombinant tumor necrosis factor: Its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines
15. The role of tumor-specific Lyt-1 +2- T cells in eradicating tumor cells in vivo. I. Lyt-1 +2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity
16. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
17. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1 +2- lymphocytes
18. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1 +,2- T cells. Tumor eradication does not require participation of cytotoxic T cells
19. Specific immunity to Listeria monocytogenes in the absence of IFN gamma
20. Cloning of murine interferon gamma receptor cDNA: Expression in human cells mediates high-affinity binding but is not sufficient to confer sensitivity to murine interferon gamma
21. Interleukin 7 induces CD4+ T cell-dependent tumor rejection
22. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma
23. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
24. Immune response in mice that lack the interferon-gamma receptor
25. The central role of CD4(+) T cells in the antitumor immune response
26. In vivo priming of two distinct antitumor effector populations: The role of MHC class expression
27. Specific and nonspecific immunity in the prevention of spontaneous tumours
28. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins
29. A unique tumor antigen produced by a single amino acid substitution
30. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
31. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
32. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma
33. Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma
34. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
35. Immunity to methylcholanthrene-induced sarcomas
36. B cells inhibit induction of T cell-dependent tumor immunity
37. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
38. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
39. Tumor immunology
40. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
41. Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo
42. Immune interferon: A pleiotropic lymphokine with multiple effects
43. Distribution of interferon-gamma receptor in human tissues
44. Human tumor necrosis factor produced by human B-cell lines: Synergistic cytotoxic interaction with human interferon